CA
NZ
UK
AU
IND
US
Neuphoria Therapeutics (NASDAQ: NEUP) shares closed up 18% at $3.92 after the company and Scancell Holdings plc (AIM: SCLP) finalized an agreement for an all-stock merger, one of the more significant corporate actions among the disclosed biopharma names this session.
China SXT Pharmaceuticals (NASDAQ: SXTC) shares closed down 84% at $0.33 after the company announced a $9 million registered direct offering, one of the most severe single-day declines among the disclosed biopharma names this session.
MindWalk Holdings (NASDAQ: HYFT) shares closed down 18% at $1.18 after the company reported a quarterly loss of $0.06 per share, missing the $0.05 consensus by 20%.
A cluster of biopharma names moved sharply in the same session on a wide range of corporate, clinical, and financing news, spanning one standout earnings-driven rally, one severe dilution-driven collapse, a finalized cross-border merger, and five separate declines tied to financing actions, an earnings …
Niki BioSolutions, Inc. (NASDAQ: NIKI) shares closed down 5% at $8.58 after the company revealed that DiamiR Biosciences, its subsidiary, has contracted with Progressive Medical Research (PMR) to deliver Apolipoprotein E (APOE) genotyping services.
HCW Biologics (NASDAQ: HCWB) shares closed down 14% at $2.88 after the company requested a Type B pre-IND consultation with the FDA to coordinate on the clinical framework and regulatory roadmap for HCW11-018b.
Jaguar Health (NASDAQ: JAGX) shares closed down 23% at $1.03 after the company disclosed that its subsidiary, Napo Pharmaceuticals, has supplied a proprietary oral solution formulation of crofelemer for compassionate use.
Solventum (NYSE:SOLV) shares surged more than 7 percent in Tuesday trading after UBS upgraded the stock to Buy from Neutral and raised its price target to $95 from $78, citing improved confidence in the company's turnaround trajectory ahead of its August 5 second-quarter earnings …
UnitedHealth Group (NYSE:UNH) shares are rallying alongside a broad managed-care sector lift after peer Centene (NYSE:CNC) raised its full-year 2026 profit guidance and posted a second-quarter earnings beat, citing improved medical cost control with its health benefits ratio falling to 89.6 percent from 93.0 …
Oscar Health (NYSE:OSCR) shares are rallying alongside broader managed care peers in Tuesday trading after Centene (NYSE:CNC) reported a strong second-quarter profit of over $1.1 billion and an improved medical loss ratio of 89.6 percent, easing sector-wide fears about Affordable Care Act marketplace cost …
Please wait processing your request...